lecture 14 Flashcards

natural history of HIV diseas

1
Q

What is the clinical course of HIV?

A
  • measure HIV viral load
  • measure CD4 cells - hallmark immunological abnormality in HIV
  • many many immunological abnormalities with HIV but CD4 count is the one that is most commonly measured in the clinic

viral load

  • days to weeks before you start to see HIV in the plasma
  • w/i a couple of weeks you get massive replication so that if you measure someones virus in plasma shortly after infection you get Acute HIV syndrome - wide dissemination of virus, seeding of lymphoid organs
  • millions of copies/mL
  • then immune response kicks in, CD4, CD8, (relatively useless) antibody
  • causes viral load to decline (some level of control of viral replication)
  • viral load sits at a steady state for many years
  • steady state ≠ no viral replication, it means that production = clearance
  • this set point is variable amongst people
  • on average for 10 years stays under control
  • after 10 years lose control and viral load continues to increase again

CD4 T cell count

  • at the same time you have very dramatic changes of CD4 T cell count
  • this is essentially what makes you unwell
  • after primary infection you get “acute phase of CD4 depletion”
  • this is a transient decline, sometimes to very low levels
  • but then you get recovery, usually to a normal level
  • normal CD4 T cell count believed to be > 500 ( probably > 900)
  • rarely returns to pre-infection levels
  • overtime: gradual, slow depletion of T cells (~ 50 cells/year)
  • while the virus is chipping away at these T cells you can remain pretty well for a period of time
  • until you reach a critically low level of T cells and that’s when you start running into trouble
  • development of constitutional symptoms, opportunistic diseases (AIDS), and invariable death
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What happens in the GIT/mucosa during acute infection?

A
  • massive depletion of CD4+ T cells from GIT
  • normally have lots of active CD4+ T cells here
  • wiped out
  • the amount of T cells that we lose in blood is probably an underestimate of the amount of T cells that we lose in the whole body bc of the number we lose in the GIT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the chronology of CD4 T-cell loss and disease?

A

Primary infection

  • glandular fever like illness in about 50% of people
    • fever
    • myalgia
    • lymphadenopathy
  • other 50% are completely asymptomatic and have no idea that they have picked up HIV
  • very rarely you can get quite sick during this period with meningo encephalitis

advanced (CD4 500), things aren’t quite right

  • see a range of autoimmune diseases that don’t necessarily ring a bell that suggests this must be HIV
  • seen in people without HIV
  • Guillan-Barre
  • idiopathic thrombocytopenia
  • even in this early stage there is immune dysregulation

500 > CD4 > 200

  • not normal CD4 cell count but still don’t see HIV defining diseases
  • range of other illnesses
  • e.g. Tuberculosis (probably the most important co-infection globally that occurs with greater frequency and greater severity in people with HIV, even when they only have intermediate immunosuppression)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is CD4+ T-cell homeostasis?

A
  • arise from CD34+ progenitor cells in the bone marrow
  • progenitor cells move to the thymus where they are educated to recognise self and non-self antigens
  • undergo maturation in the thymus and exit as naive T cells
  • maintained over life largely through homeostatic proliferation
  • when they contact an antigen that they are designed to recognise they expand, become effector cells that remove that foreign antigen, once business is done they revert back to a central memory state/cell
  • this forms immunological memory for life
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are causes of CD4+ T-cell decline?

A

Increased destruction

  • direction infection
    • GIT&raquo_space;» blood
    • incomplete reverse transcription in naive T-cells, don’t have to get productive infection to eliminate the T cell
  • Indirect effects
    • syncitium formation, non-infected cells start to gather around the infected cell because it presents gp120 on the surface , therefore eliminating uninfected cells
    • apoptosis
    • immune activation - in the effort to respond to HIV you get significant clonal expansion of HIV specific CD8 T cells and CD4 T cells, it’s as if the immune system goes into overdrive, immune activation of lots of cycles of proliferation will ultimately kill the cell because it reaches the end of its proliferative capacity
    • lymph node fibrosis

Impaired production

  • thymus
  • CD34+ progenitor cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Why is CD4 T-cell depletion variable?

A

Viral factors

  • CXCR4 virus accelerated T-cell loss
  • Nef deleted virus limits T-cell loss
  • co-infection with other viruses e.g. CMV, GBV-C

Host factors

  • immune response
    • HLA type (lower viral set point, lose T cells at a slower rate)
  • genetic factors
    • e.g. CCR5 delta 32 heterozygote has slower disease progression
  • Age
    • impaired thymic function in very young and very old
    • if you are very young when your thymus is developing and it takes a hit you notice the loss of thymic function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Why is HLA type important for immune response?

A
  • B13, B27, B51, B57 good prognosis
  • A23, B37, B49 rapid disease progression
  • certain HLA molecules present HIV epitopes more effectively which enhances the adaptive immune response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is HIV-induced immunopathology associated with depletion and/or dysfunction of other cells?

A
  • CD8+ CTLs: abnormally high during acute phase, decline at later stages
  • NK cells: impaired numbers and function
  • monocytes and macrophages: defects in chemotaxis, inability to promote T-cell proliferation, defects in Fc receptor function
  • B-cells: increased production of IgG and IgA but decreased antibody responses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How do we see chronic immune activation in people with HIV?

A
  • even though we think about HIV as immunodeficiency, the other way to think about it is the immune system going into overdrive
  • markers of immune activation that are elevated in HIV infection
  • e.g. T-cells: HLA-DR, CD38, sCD26, sCD30
  • cellular and soluble markers found in T-cells, monocytes, B-cells, NK cells, DCs, hepatocytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What causes immune activation?

A

Mucosal depletion of CD4 T-cells

  • increased microbial translocation
  • activation of TLR4 by bacterial products (LPS)

Activation of innate immune response (pDCs)

  • HIV RNA is a TLR7/8 ligand
  • increased plasma IFN-alpha

Cytomegalovirus (CMV)-specific response
- expansion of CMV-specific activated CD4+ and CD8+ T-cells
(also seen in the elderly in the absence of HIV)

Loss of T regulatory cells
(normally inhibits immune response)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is HIV-induced immunopathology associated with innate immune cells?

A
  • plasmacytoid dendritic cell –> IFN-alpha –> CD4+ T-cell
  • HIV stimulates monocyte/macrophage to release IL-6, TNF-alpha, IL-10, CXCL10
    • stimulate CD4
  • HIV stimulates CD4 directly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How can we use animal models to understand CD4 decline and immune activation?

A
  • rhesus macaque
  • sooty mangabey

if you put SIV into a rhesus macaque (not natural host) it develops a very similar illness to HIV, loses CD4 T cells and develops AIDS

if you put it into a sooty mangabey, the animals remain healthy
many in west africa where they are endemic, many are naturally infected with SIV, and it seems to cause no problem
tends to ignore the virus which seems to help it, unlike us

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How do these models of pathogenic and non-pathogenic SIV compare to HIV?

A
  • HIV/SIV RNA is high in all
  • CD4 decline in humans and RM (pathogenic), but not SM (non-pathogenic)
  • immune activation in humans and RM, not SM
  • LPS increased in humans and RM, low in SM
  • GIT depletion in humans in RM but only early in SM, otherwise no
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How do the antiretroviral therapy drugs act?

A
  • cellular chemokine receptor antagonists (attack co-receptor binding step)
  • fusion inhibitors
  • reverse transcriptase inhibitors (NRTIs and NNRTIs)
  • integrase inhibitors
  • protease inhibitors
  • probably around 30 drugs that act on these different pathways
  • main principle of treatment is that we never just use a single drug
  • if you target multiple steps etc you limit the capacity for the virus to escape
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How does the pill burden compare between 1996 and 2014?

A
  • much less, now can take one pill instead of 20

- one tablet will contain three antiretroviral drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What happens when you put people on treatment?

A
  • cART leads to rapid decline in HIV RNA and CD4 recovery
  • within a month the virus will disappear from blood –> still there but beneath the detection of the assays we have available (20/mL)
  • once you can control the virus like this, the CD4 T cells are able to recover in most patients
  • recovery phase of CD4 T cells usually takes a lot longer
  • in most patients if you start not too late, CD4 T cell count will return to above 500
17
Q

How has patient survival changed with the introduction of ARTs?

A
  • dramatic improvement of life expectancy
  • danish cohort study
  • before ART dramatic reduction in life expectancy - chance of getting to 50 with HIV was virtually negligible
  • early ARTs saw dramatic improval in survavl to 50 (but not perfect)
  • later ARTs in early 2000s improved on this but still not normal
  • recent data suggests that if you start treatment before your CD4 T cell count gets less than 200 and you don’t have other co-whatevers your life expectancy is normal
18
Q

What about access to cART in low and middle income countries?

A
  • 10 million people in low and middle income countries now on cART
  • in 2012 about 60% of people who needed treatment were getting treatment
19
Q

What is one of the challenges in treatment?

A
  • finding people with HIV
  • getting them onto treatment and making sure they stay on it
  • the ‘HIV cascade’
  • of all the people living with HIV, probably only about 50% know that they are infected
  • and of those that know only about 60% are on ART (30% of total)
  • only 25% of all with HIV are living with a suppressed viral load
  • people think now that we could see the end of HIV infections if you treated everyone
  • lots of implementation research
  • e.g. in australia 80% of people with HIV have undetectable viral loads due to being on treatment
20
Q

What is persistence of non AIDS deaths?

A
  • decline of AIDS but persistence of non AIDS deaths
  • range of illnesses seen that are more common in people with HIV on treatment than in age matched controls
  • people in the late 2000s are dying far less frequently from HIV/AIDS than in the late 90s
  • decline in people dying of chronic viral hepatitis
  • not much change in non-AIDS malignancy (e.g. lymphoma)
  • still see an increased rate of death in people with HIV due to acute myocardial infarction
21
Q

How does significant morbidity perist on HAART?

A
  • cART toxicity
  • HIV
  • immune dysfunction
  • phenotype of accelerated ageing

all contribute to:

  • cardiovascular disease
  • metabolic disorders
  • neurocognitive abnormality
  • liver disease
  • renal disease
  • bone disorders
  • malignancy
  • frailty
22
Q

What is one reason why we still have immune dysfunction in patients on cART?

A
  • CD4 T-cell recovery is variable
  • some recover really well
  • in others it takes a lot longer, or they never get up to normal
23
Q

What are the reasons for this variability in CD4-T cell recovery?

A
  • CD4+ T-cell recovery after 7 years of cART is associated with baseline CD4+ T-cell count

biological determinants:

  • viral factors
    • CXCR4 using results in poorer reconstitution
    • co-infection with other viruses e.g. hep C virus
  • host factors
    – genetic factors
    > CCR5 mutations
    > IL-7 receptor mutations
    – residual immune function
    – thymus function
    > age
24
Q

What are some of the immune abnormalities in patients on cART?

A
  • similar to ageing

Untreated HIV infection

  • expanded CMV-specific CD8 cells
  • expanded CD28-CD57+ CD8 T cells
  • reduced T cell repertoire
  • increased T cell activation
  • low IL-2, high IFN-gamma (CD8 T cells)
  • reduced thymus function
  • low CD4/CD8 ratio
  • low naive/memory ratio
  • increased IL-6
  • reduced response to vaccines
  • reduced innate immune function

Long-term (5-10years) treated HIV infection

  • expanded CMV-specific CD8 cells
  • expanded CD28-CD57+ CD8 T cells
  • reduced T cell repertoire (low CD4 nadir)
  • increased T cell activation
  • unknown if low IL-2, high IFN-gamma (CD8 T cells)
  • do not have reduced thymus function
  • low CD4/CD8 ratio
  • low naive/memory ratio (low CD4 nadir)
  • increased IL-6
  • possible reduced response to vaccines (CD4 nadir)
  • reduced innate immune function
25
Q

What are strategies for HIV prevention?

A

Behavioural

  • education
  • testing
  • condoms

Biomedical

  • vaccines
  • circumcision
  • microbicides
  • antiretroviral
    • PREP
    • treatment as prevention
  • treat sexually transmitted infection
26
Q

What are components for an effective vaccine response?

A
  • do not currently have a vaccine for HIV
  • what do we really want from a vaccine?
  • CTLs or B-cells/neutralising antibodies
  • A B cell based vaccine would prevent you ever getting infected as the HIV virus would be neutralised before it could enter the cell
  • T cell based vaccine that relies on very quick detection of an infected cell
27
Q

What have been attempted vaccine approaches?

A

Recombinant proteins

  • good antibody but poor T-cell responses
  • no protection

DNA vaccines
- good T-cells responses but poor antibody responses

Live vector vaccines

  • non-replicating poxvirus expressing HIV-1 genes –> good T-cell responses
  • Ad5 virus
    • STEP trial 2008
    • not effective
    • possibly increased risk of infection

Live attenuated virus
- potentially unsafe

Prime boost
- DNA + protein or vector

Broadly neutralising antibodies

CMV vectors
- persistent antigen presentation

28
Q

What is the only trial to have shown some level of effectiveness?

A
  • Thai trial: prime/boost partially effective
  • ALVAC (canarypox) x2 + gp120 x3
  • N=16,000
  • reduced risk by 30%
  • some thought a good result because it showed vaccine efficacy
  • some thought it was a bad result because not high enough
  • big problem for the field is to know what vaccine in which to invest… lots of money
29
Q

What did the DNA prime recombinant Ad5 boost show?

A
  • no protection
  • DNA vaccine (gag, env, nef, and pol)
  • weeks 0, 4, and 8
    • rAD5 boost (gag-pol protein and env) week 24
  • stopped part way through the study because of lack of efficacy
  • even perhaps a suggestion of increased infection
  • really made people re-think what are doing
30
Q

What are broadly neutralising antibodies?

A
  • can “neutralise” a large number of viruses
  • are directed against highly conserved regions of envelope that are “hidden”
  • detected after 1-2 years of infection and of limited help to patient
31
Q

What do we hope for the future?

A
  • synthesis of broadly neutralising antibodies in vitro
  • once you know the broadly neutralising Ab and know what it is binding to there are ways of engineering B cells in vitro to produce these bnAbs
  • look very promising in monkey models
  • CMV vectors promising in macaques
32
Q

What are unusual features of CMV vectors?

A

have unique properties of:

  • unconventional MHC-II-restricted CD8+ T-cells
  • breadth of epitope recognition
  • promiscuity
33
Q

How does circumcision reduce acquisition of HIV?

A
  • by 70%

- due to langerhan cells in the foreskin